Cidara Therapeutics (NASDAQ:CDTX) Getting Somewhat Favorable News Coverage, Analysis Shows

News articles about Cidara Therapeutics (NASDAQ:CDTX) have been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Cidara Therapeutics earned a news impact score of 0.23 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 46.0128871576673 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Shares of NASDAQ:CDTX opened at $4.00 on Friday. The company has a debt-to-equity ratio of 0.12, a current ratio of 6.43 and a quick ratio of 6.43. The stock has a market cap of $83.08, a price-to-earnings ratio of -1.26 and a beta of 1.70. Cidara Therapeutics has a twelve month low of $4.00 and a twelve month high of $8.80.

How to Become a New Pot Stock Millionaire

Cidara Therapeutics (NASDAQ:CDTX) last issued its earnings results on Tuesday, February 27th. The biotechnology company reported ($0.69) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.05. analysts predict that Cidara Therapeutics will post -2.6 EPS for the current fiscal year.

Several equities analysts recently weighed in on the stock. Cantor Fitzgerald set a $15.00 price target on shares of Cidara Therapeutics and gave the company a “buy” rating in a research report on Thursday, March 8th. Zacks Investment Research lowered shares of Cidara Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, January 12th. One analyst has rated the stock with a sell rating, two have issued a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. Cidara Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $13.38.

ILLEGAL ACTIVITY WARNING: “Cidara Therapeutics (NASDAQ:CDTX) Getting Somewhat Favorable News Coverage, Analysis Shows” was reported by BBNS and is the property of of BBNS. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international copyright law. The original version of this news story can be accessed at https://baseballnewssource.com/2018/04/01/cidara-therapeutics-cdtx-earning-somewhat-favorable-news-coverage-report-shows/1992246.html.

Cidara Therapeutics Company Profile

Cidara Therapeutics, Inc, formerly K2 Therapeutics, Inc, is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections.

Insider Buying and Selling by Quarter for Cidara Therapeutics (NASDAQ:CDTX)

Receive News & Ratings for Cidara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Red Sox Tie Record for Best Start After 17 Games
Red Sox Tie Record for Best Start After 17 Games
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Rick Porcello’s Strong Start Gives Boost to Red Sox
Rick Porcello’s Strong Start Gives Boost to Red Sox
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Xander Bogaerts Goes on Red Sox DL
Xander Bogaerts Goes on Red Sox DL


Leave a Reply

 
© 2006-2018 BBNS.